Exploratory retrospective study of risk factors for thromboembolism treated with multi-kinase inhibitor pazopanib or lenvatinib
| Autor: | Yoshihiro Matsumoto, Hitoshi Kusaba, Hiroshi Ariyama, Ryuji Yasumatsu, Eishi Baba, Junji Kishimoto, Makoto Endo, Shohei Moriyama, Toshifumi Fujiwara, Nokitaka Setsu, Koichi Akashi, Takahiro Wakasaki, Kenji Tsuchihashi, Kenta Nio, Yasuharu Nakashima, Mitsuhiro Fukata, Kyoko Yamaguchi, Mamoru Ito, Tomoyasu Yoshihiro, Keisuke Taguchi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Univariate analysis medicine.medical_specialty business.industry Incidence (epidemiology) Cancer Retrospective cohort study General Medicine medicine.disease Clinical trial Pazopanib chemistry.chemical_compound chemistry Internal medicine Medicine Risk factor business Lenvatinib medicine.drug |
| Zdroj: | International Journal of Surgery Oncology. 5:e891-e896 |
| ISSN: | 2471-3864 |
| Popis: | Tyrosine kinase inhibitors (TKI) work against various types of cancer by inhibiting angiogenic signaling. Little is understood about the incidence, characteristics, and risk factors associated with thromboembolism induced by TKI in routine clinical practice. We retrospectively analyzed data derived from 29 patients with thyroid cancer or soft tissue sarcoma (STS) treated with lenvatinib (n=10) and pazopanib (n=19). Eight (arterial n=4; venous n=4) thromboembolic events developed in 6 (20%) patients. Thromboembolisms occurred during a mean of 149 (range, 42–847) days from starting TKI. The primary disease progressed in all patients with thromboembolism. The overall survival durations of patientswith and without improved thromboembolism were 572 [95% confidence interval (CI), 225– 918] and 176 (95% CI, 84–394) days, respectively, which did not significantly differ (P=0.33). Patients with and without improved thromboembolism survived after onset for 122 (95% CI, 71–173) versus 27 (95%CI, 21–42) days (P=0.049), which significantly differed. Univariate analysis and variate selection for multivariate analysis selected a history of thromboembolism as the most powerful risk factor for new thromboembolism. In summary, the frequency of thromboembolism in clinical practice was higher than that in previous clinical trials. Furthermore, a history of thromboembolism was a risk factor for the development of new thromboembolism in patients treated with TKI. Thromboembolism developed particularly as the primary disease progressed. Our findings require validation in a large-scale study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|